b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30900516</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>15</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>15</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1557-9077</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>29</Volume>\n                    <Issue>4</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>04</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Thyroid : official journal of the American Thyroid Association</Title>\n                <ISOAbbreviation>Thyroid</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Controversies, Consensus, and Collaboration in the Use of <sup>131</sup>I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>461-470</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1089/thy.2018.0597</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Publication of the 2015 American Thyroid Association (ATA) management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met with disagreement by the extended nuclear medicine community with regard to some of the recommendations related to the diagnostic and therapeutic use of radioiodine (<sup>131</sup>I). Because of these concerns, the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging declined to endorse the ATA guidelines. As a result of these differences in opinion, patients and clinicians risk receiving conflicting advice with regard to several key thyroid cancer management issues.</AbstractText>\n                <AbstractText Label="SUMMARY">To address some of the differences in opinion and controversies associated with the therapeutic uses of <sup>131</sup>I in differentiated thyroid cancer constructively, the ATA, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association each sent senior leadership and subject-matter experts to a two-day interactive meeting. The goals of this first meeting were to (i) formalize the dialogue and activities between the four societies; (ii) discuss indications for <sup>131</sup>I adjuvant treatment; (iii) define the optimal prescribed activity of <sup>131</sup>I for adjuvant treatment; and (iv) clarify the definition and classification of <sup>131</sup>I-refractory thyroid cancer.</AbstractText>\n                <AbstractText Label="CONCLUSION">By fostering an open, productive, and evidence-based discussion, the Martinique meeting restored trust, confidence, and a sense of collegiality between individuals and organizations that are committed to optimal thyroid disease management. The result of this first meeting is a set of nine principles (The Martinique Principles) that (i) describe a commitment to proactive, purposeful, and inclusive interdisciplinary cooperation; (ii) define the goals of <sup>131</sup>I therapy as remnant ablation, adjuvant treatment, or treatment of known disease; (iii) describe the importance of evaluating postoperative disease status and multiple other factors beyond clinicopathologic staging in <sup>131</sup>I therapy decision making; (iv) recognize that the optimal administered activity of <sup>131</sup>I adjuvant treatment cannot be definitely determined from the published literature; and (v) acknowledge that current definitions of <sup>131</sup>I-refractory disease are suboptimal and do not represent definitive criteria to mandate whether <sup>131</sup>I therapy should be recommended.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Tuttle</LastName>\n                    <ForeName>R Michael</ForeName>\n                    <Initials>RM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>1 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ahuja</LastName>\n                    <ForeName>Sukhjeet</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>2 Evidence and Quality, Society of Nuclear Medicine and Molecular Imaing, Reston, Virginia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Avram</LastName>\n                    <ForeName>Anca M</ForeName>\n                    <Initials>AM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>3 Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bernet</LastName>\n                    <ForeName>Victor J</ForeName>\n                    <Initials>VJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>4 Division of Endocrinology, Mayo Clinic College of Medicine, Jacksonville, Florida.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bourguet</LastName>\n                    <ForeName>Patrick</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>5 Department of Nuclear Medicine, University Hospital of Martinique, Fort de France, Martinique.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>6 University of Antilles, Pointe-\xc3\xa0-Pitre, Guadeloupe.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Daniels</LastName>\n                    <ForeName>Gilbert H</ForeName>\n                    <Initials>GH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>7 Thyroid Unit, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dillehay</LastName>\n                    <ForeName>Gary</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>8 Department of Nuclear Medicine, Northwestern Memorial Hospital, Chicago, Illinois.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Draganescu</LastName>\n                    <ForeName>Ciprian</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>5 Department of Nuclear Medicine, University Hospital of Martinique, Fort de France, Martinique.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Flux</LastName>\n                    <ForeName>Glenn</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>9 Department of Physics, Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>F\xc3\xbchrer</LastName>\n                    <ForeName>Dagmar</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>10 Department of Endocrinology and Metabolism, University Hospital Essen, Essen, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Giovanella</LastName>\n                    <ForeName>Luca</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>11 Clinic of Nuclear Medicine and Thyroid Center, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>12 Clinic for Nuclear Medicine, University of Z\xc3\xbcrich, Z\xc3\xbcrich, Switzerland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Greenspan</LastName>\n                    <ForeName>Bennett</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>13 North Augusta, South Carolina.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Luster</LastName>\n                    <ForeName>Markus</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>14 Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Muylle</LastName>\n                    <ForeName>Kristoff</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>15 Department of Nuclear Medicine, University Hospital Brussels (UZ Brussel, VUB), Brussels, Belgium.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>16 European Association of Nuclear Medicine, Vienna, Austria.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Smit</LastName>\n                    <ForeName>Johannes W A</ForeName>\n                    <Initials>JWA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>17 Department of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Van Nostrand</LastName>\n                    <ForeName>Douglas</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>18 Georgetown University School of Medicine, Washington Hospital Center, Washington, DC.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Verburg</LastName>\n                    <ForeName>Frederik A</ForeName>\n                    <Initials>FA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>14 Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Heged\xc3\xbcs</LastName>\n                    <ForeName>Laszlo</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>19 Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016446">Consensus Development Conference</PublicationType>\n                <PublicationType UI="D016421">Editorial</PublicationType>\n                <PublicationType UI="D017065">Practice Guideline</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Thyroid</MedlineTA>\n            <NlmUniqueID>9104317</NlmUniqueID>\n            <ISSNLinking>1050-7256</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName>\n                <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018787" MajorTopicYN="N">Radiation Oncology</DescriptorName>\n                <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">adjuvant therapy</Keyword>\n            <Keyword MajorTopicYN="Y">consensus</Keyword>\n            <Keyword MajorTopicYN="Y">differentiated thyroid cancer</Keyword>\n            <Keyword MajorTopicYN="Y">radioiodine-refractory thyroid cancer</Keyword>\n            <Keyword MajorTopicYN="Y">remnant ablation</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>16</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30900516</ArticleId>\n            <ArticleId IdType="doi">10.1089/thy.2018.0597</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'